{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 1 October 2003 \line \line {\b Phase III trials 
of Tarceva plus chemotherapy in lung cancer patients do not meet primary endpoint} \line Ongoing 
programme studying Tarceva in a variety of solid tumor types to continue\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Roche 
(SWX Zurich) , Genentech, Inc. (NYSE:DNA) South San Francisco, USA and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) 
Melville, USA, today announced that the primary endpoint of improving overall survival was not met in 
two first-line randomised controlled Phase III studies of Tarceva (erlotinib) plus standard chemotherapy 
in advanced non-small cell lung cancer patients. \line In light of data of comparable studies 
with a competitive product, the results of this study are not unexpected. The outcome of the two studies 
does not affect the financial projections communicated earlier by Roche.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 \u8220?Further 
work is needed to provide more insight into the role of EGFR inhibitors combined with chemotherapy in 
this setting,\u8221? said William M. Burns, Head of Roche Pharmaceuticals. \u8220?In order to assess the therapeutic 
potential of EGFR inhibition, we will continue to analyse the data for potential subsets of patients 
who are more likely to benefit from treatment with Tarceva in combination with chemotherapy. We will 
continue our clinical development programme and believe Tarceva may have utility in treating a variety 
of other cancers.\u8221? \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 The two studies are part of an ongoing comprehensive clinical 
development programme, which includes a Phase III study of Tarceva as a single-agent in a second/third-line 
setting, a Phase II study of Tarceva as a single-agent in bronchioloavelar cell carcinoma (BAC) and 
a Phase I/II trial of Tarceva in combination with Avastin. In a phase II study Tarceva has shown effectiveness 
in brain cancer (glioma).\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Tarceva is a new form of anti-cancer treatment currently 
being tested in a variety of tumour types. It is a small molecule that works by blocking the activity 
of an enzyme called epidermal growth factor receptor (EGFR) tyrosine kinase, which helps communicate 
information within the cancer cell. EGFR, also known as HER1, is found on the surface of many tumour 
cells and may be involved in the growth and virulence of those cells. Tarceva is designed to inhibit 
the tyrosine kinase activity of the EGFR signaling pathway inside the cell, which may block tumour growth. 
\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Non-Small Cell Lung Cancer} \line According to 
the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial 
cancer each year, causing approximately 1.1 million deaths annually. According to the National Cancer 
Institute, lung cancer is the single largest cause of cancer deaths in the United States, and is responsible 
for nearly 30 percent of cancer deaths in the country. Non-small cell lung cancer is the most common 
form of the disease and accounts for almost 80 percent of all lung cancers.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About 
the Alliance} \line Genentech is a leading biotechnology company that discovers, develops, 
manufactures, and commercializes biotherapeutics for significant unmet medical needs. Sixteen of the 
currently approved biotechnology products originated from, or are based on Genentech science. Genentech 
manufactures and commercializes 11 biotechnology products in the United States. The company has headquarters 
in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For 
additional information about the company, please visit the Internet (http://www.gene.com).\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 OSI 
Pharmaceuticals is a leading biotechnology company focused on the discovery, development, and commercialization 
of high-quality, next-generation oncology products that both extend and improve the quality-of-life 
for cancer patients worldwide. OSI has a balanced pipeline of oncology drug candidates that includes 
both next-generation cytotoxic agents and novel mechanism-based, gene-targeted therapeutics focused 
in the areas of signal transduction and apoptosis. OSI has a commercial presence in the U.S. oncology 
market where it exclusively markets Novantrone (mitoxantrone concentrate for injection) for approved 
oncology indications, and Gelclair for the relief of pain associated with oral mucositis.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Headquartered 
in Basel, Switzerland, Roche is one of the world\u8217?s leading innovation-driven healthcare groups. Its 
core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market 
and is the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. 
As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group 
contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche employs 
roughly 65,000 people in 150 countries. The Group has alliances and research and development agreements 
with numerous partners, including majority ownership interests in Genentech and Chugai. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Roche 
in Oncology} \line Within the last five years Roche has become the world\u8217?s leading provider 
of anti-cancer treatments, supportive care products and diagnostics. Its oncology business includes 
an unprecedented three marketed products with survival benefit; Herceptin, MabThera and Xeloda, treating 
a range of malignancies - breast cancer, non-Hodgkin\u8217?s lymphoma and colorectal cancer. Other key products 
include NeoRecormon (anaemia in various cancer settings), Bondronat (hypercalcemia of malignancy), Roferon-A 
(leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma) and Kytril (chemotherapy and 
radiotherapy-induced nausea and vomiting). A total of 2.9 billion Swiss francs in oncology product sales 
were recorded for the first six months of 2003. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Roche\u8217?s products in development 
also promise survival benefit with Avastin. In a recent study Avastin increased survival duration by 
30% when combined with first-line chemotherapy for patients with advanced colorectal cancer.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Roche 
is developing new tests which will have a significant impact on disease management for cancer patients 
in the future. With a broad portfolio of tumour markers for prostate, colorectal, liver, ovarian, breast, 
stomach, pancreas and lung cancer, as well as a range of molecular oncology tests, we will continue 
to be the leaders in providing cancer focused treatments and diagnostics. Roche Oncology has four research 
sites (two in the US, Germany and Japan) and four Headquarter Development sites (two in the US, UK and 
Switzerland).\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 All trademarks used or mentioned in this release are legally 
protected.\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}